Close menu

October 6th, 2021 | 12:32 CEST

Valneva, Cardiol Therapeutics, BioNTech - New vaccines needed against Corona

  • Biotechnology
Photo credits:

Johnson & Johnson's new study shows the booster vaccine improves protection against severe Corona disease by 75%. According to the New York Times, the Company plans to seek approval for the booster vaccine. While the FDA has already approved BioNTech's booster vaccine for those over 65, Moderna and Johnson & Johnson have yet to receive approvals. Those are on the agency's Oct. 14 and 15 meeting schedule. BioNTech CEO Ugur Sahin stressed to the Financial Times that there must always be new formulations to stop new virus variants.

time to read: 4 minutes | Author: Armin Schulz

Table of contents:

    Valneva - Waiting for results

    Is today the day that Valneva's Corona vaccine results will be presented at the Guggenheim Vaccines and Infectious Disease Conference in the Company's presentation? If it is just information on the Chikungunya or Lyme disease vaccine, which, after all, is being co-developed with Pfizer, that would be a disappointment for those invested. At the moment, everything revolves around the Corona Inactivated vaccine, which consists of killed pathogens, i.e. a conventional vaccination method. Results have been announced for early in the fourth quarter.

    If the Phase 3 clinical trial produces positive results, share price jumps can be expected. This vaccine could persuade vaccine skeptics to vaccinate, paving the way for herd immunity. The dead vaccine method is proven, has fewer side effects and is much easier to store. However, vaccine protection must be refreshed after a few years. Another advantage for Valneva could be the existence of the Delta mutant since it is already present during the study. However, as mentioned, this presupposes correspondingly positive results.

    The Company has recently announced good news for the Lyme disease vaccine. It was shown that antibodies in the blood were still above baseline even after 18 months but had decreased over time. A booster vaccination would therefore be necessary. The share is trending sideways after the GAP. Currently, it all depends on the results. In the event of negative results, disappointed shareholders will certainly dump their shares. The stock belongs on the watch list to be able to react in case of related news.

    Cardiol Therapeutics - New study underway

    Canada-based Cardiol Therapeutics specializes in cannabidiol as an anti-inflammatory agent for heart conditions. There are increased heart problems in many Covid patients. The Company's lead product CardiolRx is being investigated in a Phase II/III clinical trial in hospitalized Corona sufferers who have cardiovascular complications. The concentrated cannabidiol drug is taken orally.

    On August 24, the Company received the green light from the U.S. FDA for its IND application submitted for a Phase II clinical trial of CardiolRx in acute myocarditis. The Company wants to gain insights into the extent to which the inflamed heart muscle can recover by taking CardiolRx.

    The Company is also constantly striving to increase its visibility. Cardiol Therapeutics took a big step on August 9, when the stock was listed on NASDAQ. On September 28, the Company presented at the Cantor Virtual Global Healthcare Conference. On October 14, the Company will participate in the International Investment Forum, where attendees can also ask questions. You can register here!

    Trading at CAD 2.66 in early August, the stock rose as high as CAD 6.19 by September 27. In the wake of the Pfizer chief's statement regarding a possible end to the Corona Crisis, the stock also fell back to CAD 4.45. Yet, heart muscle inflammation is not a purely Corona phenomenon. A Canadian analyst sees a first price target at CAD 12.50. The analysts of GBC expect in the long term even CAD 17.49.

    BioNTech - Growth prospects muted

    On August 10, BioNTech was worth more than Daimler and Bayer combined, with a market capitalization of more than USD 100 billion. But since then, at least in terms of the share price, things have not been going well. From its former value of EUR 395, the stock has almost halved to EUR 198.60. The crash occurred despite supposedly positive news, such as the release of new vaccination groups and the approval of the booster vaccination for over-65s in the USA. One possible reason, as paradoxical as it sounds, is the success of the vaccination. Since then, the number of deaths has declined, especially in the vulnerable age group.

    At the same time, the competition is catching up, and Merck, for example, has a promising drug against Corona in a clinical trial, which, if approved, could reduce the willingness to vaccinate. Vaccine skeptics prefer to wait for alternative remedies to Covid. So the question is, what comes next? Since the Pfizer chief said on ABC that he expects we can get back to "normal" in a year, the stock has plummeted nearly EUR 100. If the Corona money source dries up, it must continue. For example, in cancer research, where the Company can now research without financial pressure thanks to the income from the Corona vaccine.

    The share was able to stop the downward trend only at the support at EUR 203.20. On a positive note, no closing price was formed below it, so that a counterreaction to EUR 270.10 is currently possible. As an investor, one should also pay attention to the competition, such as Valneva or Merck. Good news there is also bad news for BioNTech. The valuation was too high at the beginning of August. Now it looks much more moderate, and one should not forget that Corona has cleared the way for mRNA compounds.

    The shares of all three companies are very volatile at the moment. Positive results, or better yet, approval, could see Valneva's share prices explode on the back of a proven vaccine. The same applies to Cardiol Therapeutics, which can still help patients with its drug even after Corona. BioNTech, on the other hand, is already on the market, and it is all about future prospects. The initial euphoria has faded for the time being because growth will probably only come with new preparations.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Armin Schulz

    Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.

    About the author

    Related comments:

    Commented by André Will-Laudien on May 18th, 2022 | 12:48 CEST

    Biotech stocks: BioNTech, XPhyto Therapeutics, Novavax, Valneva - Crashing, the choice remains difficult!

    • Biotechnology
    • Covid19

    For pure play vaccine companies, the environment is getting tougher. On the one hand, the winter is over, and on the other, Corona has lost its horrors, especially as the Omicron variant presented like a cold for most infected people. 77.6% of the German population have received at least one vaccination dose so far. 63.1 million people have thus already received basic immunization, and 49.5 million people went for another shot. Only 4.6 million people, or 5.5%, have already received a second booster vaccination. 18.6 million people have not been vaccinated, or 22.4% of the population. With currently only 4,000 vaccinations per day, the many millions of vaccine doses ordered are likely to remain on the shelf. For vaccine manufacturers, future orders will plummet. Which Company has a plan B in place?


    Commented by Juliane Zielonka on May 12th, 2022 | 13:07 CEST

    Cardiol Therapeutics, Tesla, Bayer AG - Instead of trading chronically overvalued shares, treat the chronically ill instead

    • Biotechnology

    No sooner does the US government under Biden seek to influence the Supreme Court in the Monsanto case than the Bayer share slides 7%. But is this share price slide justified? Bayer AG has made provisions for the possible ruling in June and set aside reserves for chronic diseases. Chronic diseases are also a focus of Cardiol Therapeutics. According to the World Health Organization (WHO), the prevalence of chronic diseases increased by 57% worldwide by 2020. Cardiol focuses on heart health in this regard. The share stands at about EUR 1.12 and is seen by analysts at an average of about EUR 7. Meanwhile, Tesla investors are currently experiencing what overvalued shares can do to their portfolios. Their CEO is speculating that he will no longer accept new customers. Why? You can read about it here...


    Commented by Fabian Lorenz on May 12th, 2022 | 11:12 CEST

    BioNTech, BYD and Desert Gold: Shares for the rebound

    • Gold
    • Electromobility
    • Biotechnology

    Is the rebound coming? After the heavy price losses of recent days and weeks, the market seems ripe for a countermovement. However, this would require a little more volume in the market. But then, especially companies that have not disappointed operationally should profit. BioNTech, for example, belongs to this group. The Company has published convincing figures, and analysts see up to 50% price potential. BYD's share price should also pick up speed again. Finally, the rapid shift to electric pureplay seems to be succeeding and HSBC has raised the price target. Gold was not a safe haven in the current correction. But it is worth looking at bombed-out stocks here as well. Desert Gold Ventures is one of them. The explorer has started a new drill program and secured financing.